Cancer Genetics, Inc. (NASDAQ: CGIX) is focused on the development of personalized genetic testing for the detection of various cancers, with the goal of significantly increasing treatment efficacy while reducing healthcare costs. CGI’s scientific advisory board includes leaders in the areas of hematological malignancies, solid tumor cancers, pharmacogenomics, and clinical trials administration. The company’s growing patent base consists of molecular-focused patents for the diagnosis, prognosis, and risk stratification of difficult-to-treat cancers, based on what the company calls “unique algorithms that take into account multiple chromosomal regions associated with particular disease outcomes or treatment decision”.
CGI is heavily involved in the area of pharmacogenomics – determining the way genetics affects a patient’s drug response – to improve treatment and even help select trial populations for clinical testing. The company offers a number of pharmacogenomics testing services, including theranostic testing for various hematological and solid tumor cancers. In 2013, CGI helped form Oncospire Genomics as an equally owned joint venture with Mayo Clinic, designed to develop and commercialize NGS (Next Generation Sequencing) panels for unmet critical oncological needs. In 2014, CGI acquired Gentris, LLC, a pharmacogenomics testing, genotyping, and biorepository services company based in Raleigh, NC, with operations in China. That same year, the company also acquired India-based Bioserve Biotechnologies Pvt. Ltd., a leader in DNA related services in India.
Based in Rutherford, New Jersey, CGI also has operations in North Carolina and California, as well as in India and China. In addition, the company has research collaborations with cancer research and treatment leaders around the world, including:
- Beth Israel Deaconess Medical Center
- Cleveland Clinic
- Columbia University
- Groupe Hospitalier Pitié Salpétriêre, Paris
- Huntsman Cancer Institute, University of Utah
- Kamineni Hospital
- Keck Medicine of USC
- Mayo Clinic
- Memorial Sloan-Kettering Cancer Center
- Moffitt Cancer Center
- National Cancer Institute
- North Shore-Long Island Jewish Health System
- University of Alabama School of Medicine
- University of Iowa Cancer Center
- Westchester Medical Center at New York Medical College
CGI’s President and CEO is Panna Sharma, founder of TSG Partners, a specialty life sciences consultancy and advisory company, where he directed the company’s strategic initiatives and growth strategy, including various public and private company turnarounds, establishing several life science capital markets indices that are still used in the life science industry.
For more information, visit www.CancerGenetics.com.
